OKYO Pharma's Urcosimod Phase 2 Data to Debut at ASCRS Annual Meeting
Event summary
- OKYO Pharma's abstract on urcosimod Phase 2 study accepted for presentation at the 2026 ASCRS Annual Meeting.
- Presentation scheduled for April 11, 2026, in Washington, DC, highlighting efficacy and safety data from the Phase 2 study.
- Urcosimod granted first IND for NCP treatment and FDA fast track designation.
- Company plans to initiate a 150-patient Phase 2b/3 trial in the first half of 2026.
The big picture
OKYO Pharma's acceptance at the ASCRS Annual Meeting underscores the growing recognition of urcosimod as a novel therapy for neuropathic corneal pain, a condition with significant unmet medical need. The company's strategic focus on advancing urcosimod through clinical trials and regulatory pathways positions it to potentially capture a niche in the ophthalmology market, where current treatments are limited and often ineffective.
What we're watching
- Clinical Validation
- Whether the Phase 2 data presented at ASCRS will reinforce urcosimod's potential as a first-in-class therapy for NCP.
- Regulatory Momentum
- The pace at which OKYO can advance urcosimod through the Phase 2b/3 trial and secure further FDA approvals.
- Market Differentiation
- How OKYO positions urcosimod against existing off-label treatments for NCP in a competitive ophthalmology market.
Our editorial coverage: